CD38 inhibitors(Lymphocyte differentiation antigen CD38 inhibitors), Hyaluronic acid modulators, ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)

Therapeutic Areas

NeoplasmsImmune System DiseasesCardiovascular Diseases+ [3]

Active Indication

Immunoglobulin Light-Chain AmyloidosisMultiple MyelomaSmoldering Multiple Myeloma+ [13]

Inactive Indication

Relapse multiple myeloma

Originator Organization

Janssen Global Services LLCGenmab, Inc.

Active Organization

Janssen Research & Development LLCJanssen Pharmaceutical KKJanssen-Cilag International NV

+ [5]

Inactive Organization

Janssen Pharmaceuticals, Inc.

Drug Highest PhaseApproved

First Approval Date

United States (01 May 2020),

Multiple Myeloma

RegulationAccelerated Approval (United States), Orphan Drug (United States)

Structure/Sequence

Sequence Code 136165

The sequence is quoted from: *****

Sequence Code 9075449L

The sequence is quoted from: *****

Sequence Code 9946743H

The sequence is quoted from: *****

Clinical Trials associated with Daratumumab/Hyaluronidase-fihj

NCT06046287

/ RecruitingPhase 2IIT

Phase IIa Study to Evaluate Daratumumab for Polyneuropathy Associated With MGUS

The goal of this clinical trial is to learn about daratumumab and hyaluronidase-fihj in patients with monoclonal gammopathy of undetermined significant (MGUS) who have been diagnosed with peripheral neuropathy suspected to be cause by paraproteinemia. The main question[s] it aims to answer are:
• how well does this medication help improve MGUS associated peripheral neuropathy
Participants will be asked be asked to get some testing done prior to starting the trial in order for us to assess your nerve damage or peripheral neuropathy. This will include blood tests, a complete neurologic examination, surveys and tests called electromyogram and nerve conduction studies. Participants that qualify for the trial will take DARZALEX FASPRO® once a week for two months, followed by every other week from months 3 to month 6.

Start Date01 Apr 2025

Sponsor / Collaborator

Georgetown University

[+1]

NCT06142396

/ RecruitingEarly Phase 1IIT

Pilot Study of Daratumumab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD) in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

The goal of this study is to assess the efficacy of induction treatment with daratumumab-hyaluronidase (dara SC) with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) for four cycles in patients with newly diagnosed multiple myeloma who have new onset renal failure. This study will also investigate the difference responses in African American (AA) patients versus non-African American patients.
The primary questions this study aims to answer are:
1. To evaluate the very good partial response rate (VGPR) after 4 cycles of Dara-CyBord.
2. To evaluate the renal response rate (RRR) after 4 cycles of Dara-CyBord.

Start Date01 Nov 2024

Sponsor / Collaborator

Augusta University Research Institute

[+1]

NCT06398457

/ RecruitingEarly Phase 1IIT

A Pilot Study of Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies (DSA) levels to low enough levels to permit patients to proceed with allogeneic peripheral blood transplant (alloBMT). Those being asked to participate have high DSA levels that puts those being asked to participate at high risk of rejecting the available donor's blood stem cells and making those being asked to participate ineligible to receive a stem cell transplant.

Start Date19 Sep 2024

Sponsor / Collaborator

The Sidney Kimmel Comprehensive Cancer Center

[+1]

100 Clinical Results associated with Daratumumab/Hyaluronidase-fihj

100 Translational Medicine associated with Daratumumab/Hyaluronidase-fihj

100 Patents (Medical) associated with Daratumumab/Hyaluronidase-fihj

Literatures (Medical) associated with Daratumumab/Hyaluronidase-fihj

01 Oct 2024·ANNALS OF HEMATOLOGY

The clinical efficacy of a daratumumab-based regimen in relapsed/refractory acute leukemia: a single-center experience

Article

Author: Li, Jing ; Luo, Lin ; Dai, Yi ; Luo, Jun ; Cheng, Peng ; Wei, Zhenbin

Abstract:

Relapsed/refractory acute leukemia (R/R-AL) is associated with a low remission rate, short survival rate, and poor prognosis. Treating R/R-AL remains challenging as there is no standardized effective regimen; hence, there is a need for efficient therapies. CD38 expression has been observed in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Daratumumab is a humanized anti-CD38 monoclonal antibody used to treat multiple myeloma and has been reported to treat R/R-AL safely and effectively. The clinical data of 10 adult patients with R/R-AL who were treated with a daratumumab-based salvage regimen between July 2018 and May 2023 at our center were analyzed retrospectively. Seven AML and three ALL cases were included in the analysis. Seven (70%) patients showed responses to the treatments (complete response [CR], 60%; partial response [PR], 10%). Of the seven responders, three underwent allogenic stem cell transplantation (ASCT), including one who underwent a second ASCT. Among the five patients with R/R AML who had prior exposure to venetoclax, three achieved a therapeutic response (two CR and one PR) when re-treated with venetoclax in combination with daratumumab. The median follow-up time was 6.15 months (0.9–21 months). Overall survival and event-free survival rates at 12 months were 68.6% and 40.0%, respectively. The main adverse events included grade 3 febrile neutropenia (20%) and grade 3 hematological toxicities (60%). The daratumumab-based salvage regimen offers patients with R/R-AL the opportunity of remission with acceptable tolerability, creating the possibility of bridging ASCT.

01 Jun 2023·Clinical pharmacokinetics

Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab.

Review

Author: Kim, Kyeongmin ; Phelps, Mitch A

Daratumumab is a fully human, monoclonal immunoglobulin G1 and a first-in-class CD38-targeting drug approved by the US Food and Drug Administration for the treatment of patients with relapsed/refractory and newly diagnosed multiple myeloma or newly diagnosed light-chain amyloidosis. CD38 is heavily expressed on malignant myeloma cells, and daratumumab exerts anti-myeloma activity via immune-mediated mechanisms, direct induction of apoptosis, and immunomodulation. Daratumumab is used as monotherapy or in combination with standard-of-care myeloma therapies, including proteasome inhibitors, immunomodulatory agents, DNA-alkylating agents, and corticosteroids. Following an intravenous infusion, daratumumab exhibits nonlinear pharmacokinetics (PK), as clearance decreases with higher doses and over time because of target-mediated effects. Dosing schedules vary depending on indications and co-administered drugs, but generally daratumumab is administered weekly for 6-9 weeks followed by a less frequent dosing regimen, once every 2-4 weeks. Daratumumab exposure is strongly correlated with efficacy, and the exposure-efficacy relationship follows a maximal effect model, whereas exposure is not correlated with safety endpoints. The approved dose of 16 mg/kg of daratumumab results in the saturation of 99% of the target at the end of weekly dosing in most patients, and high target saturation is maintained over time during the less frequent dosing schedule. Infusion-related reactions are frequently observed in patients given daratumumab, particularly with the first infusion, thus prompting long durations of infusion (~ 7 h) and splitting of the first dose across 2 days. This led to the development of a subcutaneous delivery formulation for daratumumab (Dara-SC). Dara-SC provides a similar efficacy and safety profile to intravenous daratumumab (Dara-IV) but has a much lower rate of infusion-related reactions and a shorter infusion time. Exposure-response relationships for efficacy and safety endpoints were similar between Dara-SC and Dara-IV, and co-administered drugs with either Dara-IV or Dara-SC do not significantly affect daratumumab PK. Except for baseline myeloma type and albumin level, none of the other investigated disease and patient characteristics (renal/hepatic function, age, sex, race, weight, Eastern Cooperative Oncology Group performance status) was identified to have clinically relevant effects on exposure to daratumumab monotherapy or combination therapy regimens. Dara-IV exposure was significantly lower in patients with immunoglobulin G myeloma compared with patients with non-immunoglobulin G myeloma (p < 0.0001) and in patients with a lower albumin level, whereas the overall response rate was similar regardless of the myeloma type and albumin level. Daratumumab dose adjustment is not currently recommended based on disease and patient characteristics.

01 Mar 2023·Transplantation

Anti-CD38 Monoclonal Antibodies Interfere With Isoagglutinin Detection

Article

Author: Kamar, Nassim ; Del Bello, Arnaud ; Gauthier, Katia ; Cointault, Olivier ; Vieu, Guillaume

A review.ABO-incompatible considered a safe (ABOi) procedure, kidney respecting transplantation preformed is donor-specific isoagglutinin elimination before the surgery.Hemagglutination remains the most frequently used method to detect isoagglutinin.We assessed isoagglutinin titers in a candidate for ABOi-Iiving donor kidney transplantation (A to O) who was treated by a humanized anti-CD38 IgG monoclonal antibody (daratumumab) a week before for multiple myeloma.Although IgM isoagglutinin titer was low before and after desensitization, IgG isoagglutinin titer, detected with the microcolumn agglutination method (Biorad Liss/Coombs IgG/C3d), was and remained very high (>2048) before and after desensitization using highvolume specihc immunoadsorption.The binding of daratumumab on CD38 that is highly expressed on the surface of red blood cells and myeloma cells induces their agglutination, leading to a false-pos. isoagglutination test until 2 to 6 mo postadministration.Dithiothreitol disrupts the bridging of the disulhde bonds between amino acid residues necessary for structural conformation of some proteins, such as the CD38 antigen (which presents 5 bridges).Hence, dithiothreitol prevents anti-CD38 binding on red blood cells treated and overcomes the interference of the daratumumab and agglutination tests.Other monoclonal antibodies given to treat kidney diseases could also interfere with isoagglutinin. This has to be examined carefully.

137

News (Medical) associated with Daratumumab/Hyaluronidase-fihj

10 Mar 2025

·www.fiercebiotech.com

J&J opts out of licensing Genmab\'s Darzalex challenger after look at phase 1/2 data

Among 84 patients evenly split in each study arm, HexaBody-CD38 elicited an objective response rate of 55% compared to 52% in the Darzalex arm.\n Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program.Back in 2019, the companies teamed up to develop a successor to their multiple myeloma blockbuster Darzalex, an anti-CD38 antibody. The deal gave J&J the option to license HexaBody-CD38—which was designed using Genmab tech that aims to dial up the cancer-killing power of therapeutics—after a proof-of-concept study for $150 million, plus potential milestones and royalties. Now, the Big Pharma has determined that it won’t exercise that option, according to a March 10 release. Furthermore, Genmab has decided that it won’t continue development of the monoclonal antibody.Genmab credited the discontinuation to a “thorough evaluation of the data, the market landscape and Genmab’s rigorous portfolio prioritization.”In 2020, Sanofi\'s Sarclisa (isatuximab-irfc), a CD38-directed cytolytic antibody, snared FDA approval to treat patients with relapsed or refractory multiple myeloma. Since then, the FDA has also granted the immunotherapy approval for newly treated myeloma. Under the terms of Genmab\'s agreement with J&J, the Danish company provided data from a clinical proof-of-concept study in multiple myeloma, including a head-to-head comparison with Darzalex (daratumumab).The phase 2 expansion part of the trial assessed the objective response rate (ORR) of intravenous HexaBody-CD38 versus subcutaneous daratumumab in patients with anti-CD38 antibody-naïve relapsed or refractory multiple myeloma.Among 84 patients evenly split in each arm, HexaBody-CD38 elicited an ORR of 55% compared to 52% in the daratumumab arm.The complete response rate was 7% for HexaBody-CD38 and 2% for daratumumab.Duration of response, progression-free survival and overall survival were not yet reached at the time of data cutoff. Genmab expects to share more mature data at a future medical conference. Treatment-emergent adverse events affecting more than 20% of patients in the HexaBody-CD38 arm were neutropenia, infusion-related reactions, anemia and thrombocytopenia. One patient died from a TEAE in the HexaBody-CD38 arm, while two patients died in the daratumumab arm; the three deaths were not related to the study treatment, according to Genmab. “While we are disappointed that J&J has decided not to advance HexaBody-CD38, the data confirms the clinical potential of the HexaBody platform, reinforcing its value for future applications,” Genmab CEO Jan van de Winkel, Ph.D., said in the release.The leader instead pointed to later-stage opportunities in Genmab’s pipeline, such as rinatabart sesutecan (Rina-S)—a potential challenger to AbbVie’s Elahere that Genmab gained in its $1.8 billion ProfoundBio buyout—and PD-L1x4-1BB bispecific antibody acasunlimab. Both assets are currently undergoing phase 3 testing. The pipeline discontinuation and J&J’s decision not to take up the option for HexaBody-CD38 do not impact Genmab’s 2025 financial guidance, according to the company. Analysts at William Blair called the opt-out \"unfortunate but largely expected\" in a March 10 note, adding that \"getting past the highly anticipated JNJ decision and expected share pullback now allows investors to focus on the company’s pipeline and potential blockbusters including Epkinly, Rina-S and acasunlimab.\"Since the company’s announcement, which was made around 10 a.m. ET, Genmab’s stock has dropped more than 8% from its market open price of $23.93 per share, settling at $21.98 as of 4 p.m. ET on March 10.Editor\'s note: This story was updated at 5:30 p.m. ET on March 10 to include analysis from William Blair.

License out/inPhase 2ImmunotherapyClinical ResultDrug Approval

10 Mar 2025

·pipelinereview.com

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

COPENHAGEN, Denmark I March 10, 2025 I Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio prioritization, Genmab will not pursue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance HexaBody-CD38, the data confirms the clinical potential of the HexaBody platform, reinforcing its value for future applications,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “With EPKINLY ® (epcoritamab) moving from strength to strength and two wholly owned assets, rinatabart sesutecan (Rina-S™) and acasunlimab in Phase 3 development, we are confident in the potential of our existing pipeline of innovative antibody therapeutics. Genmab intends to maintain its laser sharp focus on and disciplined investments in our promising late-stage proprietary clinical pipeline and continues to execute against our capital allocation framework ensuring future growth.” As stipulated by the development and option agreement between Genmab and J&J for HexaBody-CD38, Genmab provided J&J with data from a clinical proof-of-concept study in multiple myeloma, including a head-to-head comparison with DARZALEX FASPRO ® (daratumumab and hyaluronidase fihj). The Phase 2 expansion Part B of the study assessed the objective response rate (primary endpoint) of intravenous HexaBody-CD38 versus subcutaneous daratumumab in patients with anti-CD38 antibody- naïve relapsed or refractory multiple myeloma. Preliminary data submitted by Genmab to J&J, inclusive of 88 patients who received a study treatment and 84 patients who were response evaluable (42 in each arm), demonstrated an overall response rate (ORR) of 55% (95% CI: 39%, 70%) in the HexaBoby-CD38 IV arm vs. 52% in the daratumumab SC arm (95% CI: 36%, 68%); very good partial response (VGPR) or better rate was 29% vs. 17%; and complete response (CR) or better rate was 7% vs. 2%. Due to the relatively short follow-up time, secondary efficacy endpoints including duration of response, progression-free survival, and overall survival were not mature yet. Treatment emergent Adverse events (TEAEs) above 20% in the Hexabody-CD38 arm were neutropenia, infusion related reactions, anemia, and thrombocytopenia. No new safety findings were observed in the daratumumab arm of the study. TEAEs leading to death included one patient in the HexaBody-CD38 IV arm and two patients in the daratumumab SC arm; none of these deaths was related to the study treatment. Follow-up is ongoing and more mature data will be presented at a future medical conference. This news does not impact Genmab’s 2025 Financial Guidance. Conference Call Details Genmab will host a conference call to discuss this event today at 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT. To join the call or listen to the webcast, please register using the following link: https://genmab-investor-update-mar2025.open-exchange.net/ . An archived webcast of the call will be available at https://www.genmab.com/investor-relations . About the 3014-01 Trial 3014-01 is a Phase 1/2, open-label, multi-center trial to evaluate the safety and preliminary efficacy of HexaBody-CD38 as a monotherapy in patients with relapsed or refractory multiple myeloma and other blood cancers. The trial consists of three parts: a dose-escalation phase (Phase 1) and an expansion phase (Part A and Part B). The primary objective of Phase 1 is to determine the recommended Phase 2 dose and the maximum tolerated dose as well as establish the safety profile of HexaBody-CD38 monotherapy. The purpose of Phase 2 Expansion Part A is to assess the objective response rate of HexaBody-CD38 for patients with relapsed or refractory multiple myeloma and other blood cancers. The purpose of Phase 2 Expansion Part B is to assess the objective response rate of HexaBody-CD38 versus subcutaneous daratumumab in patients with CD38 antibody naïve relapsed or refractory multiple myeloma. More information on this trial can be found at https://www.clinicaltrials.gov (NCT04824794). About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines ® . Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X . SOURCE: Genmab

Clinical ResultPhase 2License out/inImmunotherapyPhase 3

10 Mar 2025

·firstwordpharma.com

J&J, Genmab drop antibody pitched as Darzalex successor

Genmab and Johnson & Johnson are no longer developing an anti-CD38 antibody the partners had hoped to market as a next-generation version of their megablockbuster cancer drug, Darzalex (daratumumab) — which rose to the number one spot on the pharma's top-sellers list last year, and was the seventh biggest revenue generator across all pharmaceuticals (see – Spotlight On: J&J's Darzalex joins the $10 billion club and Vital Signs: Top ten drugs of 2024).The decision comes more than a decade since the pair first teamed up on Darzalex, a CD38-targeted monoclonal antibody (mAb) that won its first full FDA approval for multiple myeloma (MM) in 2016. Three years later, J&J and Genmab agreed to use the latter's HexaBody technology to design a follow-on drug against CD38. At the time, Genmab CEO Jan van de Winkel had commented that "preclinical data suggest that HexaBody-CD38 could be superior to [Darzalex] for certain tumour cell types." He has previously described the HexaBody technology to FirstWord as "super-charged molecules with a much higher ability to kill target cells in the context of cancer by promoting clustering behavior." See – ViewPoints: What’s next for Genmab?As part of the collaboration, Genmab funded R&D activities for the candidate, GEN3014, through clinical proof-of-concept studies in MM, after which J&J could opt for a global license. But on Monday, Genmab disclosed that the pharma has decided not to exercise its option for GEN3014, and without J&J's backing, the biotech said that, "following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio prioritisation," it wouldn't continue development. The biotech's stock dropped more than 8% in Copenhagen on the news.Safety woesEarly data from a Phase I/II trial might shed some light as to why J&J decided not to move forward with GEN3014. Though Genmab said the results "showed robust clinical efficacy," the intravenous HexaBody programme did not seem to significantly improve overall response rate (ORR) compared with subcutaneous Darzalex. Of 84 evaluable patients with relapsed or refractory MM or another blood cancer, half received GEN3014 and half took the flagship drug. Patients in the GEN3014 arm saw an ORR of 55% and a complete response rate of 7%, compared with rates of 52% and 2% for Darzalex recipients.Moreover, GEN3014 was associated with a notably higher rate of severe related treatment-emergent adverse events (TEAEs), with 73.3% of patients experiencing Grade 3 or higher events compared to 18.6% with Darzalex, and related serious TEAEs occurring nearly twice as often at 22.2%. Treatment interruptions due to TEAEs were reported in 51.1% of GEN3014 patients versus 4.7% for Darzalex, while dose delays occurred in 75.6% and 34.9% of cases, respectively."While we are disappointed that J&J has decided not to advance HexaBody-CD38, the data confirms the clinical potential of the HexaBody platform, reinforcing its value for future applications," Winkel said in a company release Monday, adding that Genmab is "confident in the potential of our existing pipeline of innovative antibody therapeutics."

Drug ApprovalLicense out/inClinical ResultADC

100 Deals associated with Daratumumab/Hyaluronidase-fihj

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Immunoglobulin Light-Chain Amyloidosis	United States	Janssen Biotech, Inc.	15 Jan 2021
Multiple Myeloma	United States	Janssen Biotech, Inc.	01 May 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Smoldering Multiple Myeloma	NDA/BLA	United States	Johnson & Johnson	08 Nov 2024
Refractory Multiple Myeloma	Phase 3	United States	Janssen Research & Development LLC	27 Oct 2017
Refractory Multiple Myeloma	Phase 3	Japan	Janssen Research & Development LLC	27 Oct 2017
Refractory Multiple Myeloma	Phase 3	Australia	Janssen Research & Development LLC	27 Oct 2017
Refractory Multiple Myeloma	Phase 3	Brazil	Janssen Research & Development LLC	27 Oct 2017
Refractory Multiple Myeloma	Phase 3	Canada	Janssen Research & Development LLC	27 Oct 2017
Refractory Multiple Myeloma	Phase 3	Czechia	Janssen Research & Development LLC	27 Oct 2017
Refractory Multiple Myeloma	Phase 3	France	Janssen Research & Development LLC	27 Oct 2017
Refractory Multiple Myeloma	Phase 3	Greece	Janssen Research & Development LLC	27 Oct 2017
Refractory Multiple Myeloma	Phase 3	Israel	Janssen Research & Development LLC	27 Oct 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03277105 (COLUMBA, FDA_CDER) Manual	Phase 3	Relapse multiple myeloma \| Refractory Multiple Myeloma	522	DARZALEX FASPRO	klttzwwsyn(ybmtcajgdf) = obnychlzzo pcuuprmqap (itttnzvmnh, 35 - 47) View more	Positive	30 Jul 2024
				Intravenous Daratumumab	klttzwwsyn(ybmtcajgdf) = lfcwgnvekx pcuuprmqap (itttnzvmnh, 31 - 43) View more
NCT03871829 (CTgov)	Phase 2	Multiple Myeloma	88	Carfilzomib+Dexamethasone 40 mg (Arm A: Carfilzomib+Dexamethasone (Kd))	ngeiuoufdp = cswubhwsvl dgmolsords (ixlzvbtwqi, hgvecwflhr - zvfenkcfzk) View more	-	19 Dec 2023
				Carfilzomib+Dara-SC 1800 mg+Dexamethasone 40 mg (Arm B: Dara-SC in Combination With Kd (DKd))	ngeiuoufdp = nxgycbhnup dgmolsords (ixlzvbtwqi, jifqivipqe - qhsytwkjdj) View more
ASCO2023	Not Applicable	Multiple Myeloma	102	Arm 1 (Premedication continued)	vbexlxrnzb(vphltuhmdy) = zqugbhorfr rvtpjvdcyq (ufphtmcoqf )	Positive	31 May 2023
				Arm 2 (Premedication omitted after fourth dose)	vbexlxrnzb(vphltuhmdy) = agnrsqdftn rvtpjvdcyq (ufphtmcoqf )
NCT03277105 (COLUMBA, CTgov)	Phase 3	Refractory Multiple Myeloma	522	Daratumumab (Daratumumab IV)	slqhoexgvf = dcuqsisnyd inzntucpcz (jobaboipro, vgsyumvghk - qixlsxuqir) View more	-	27 Jul 2020
				Daratumumab (Daratumumab SC)	slqhoexgvf = sbkwvlqchy inzntucpcz (jobaboipro, jhphubqnwm - ucfuianipg) View more
EHA2020	Not Applicable	Relapse multiple myeloma	94	Daratumumab monotherapy	byyufmctut(rjvplpgqrt) = zgwfjcjplj ydmdhzhumy (lwhlwmpwqf )	Positive	14 May 2020
				Subsequent therapies	xksjijpvnz(oidvrwyess) = njzfndljbh qruianuexn (unorbbvryv )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis